z-logo
Premium
A nonparametric Bayesian basket trial design
Author(s) -
Xu Yanxun,
Müller Peter,
Tsimberidou Apostolia M.,
Berry Donald
Publication year - 2019
Publication title -
biometrical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 63
eISSN - 1521-4036
pISSN - 0323-3847
DOI - 10.1002/bimj.201700162
Subject(s) - nonparametric statistics , covariate , bayesian probability , frequentist inference , computer science , population , identification (biology) , medicine , machine learning , bayesian inference , econometrics , artificial intelligence , mathematics , biology , botany , environmental health
Targeted therapies on the basis of genomic aberrations analysis of the tumor have shown promising results in cancer prognosis and treatment. Regardless of tumor type, trials that match patients to targeted therapies for their particular genomic aberrations have become a mainstream direction of therapeutic management of patients with cancer. Therefore, finding the subpopulation of patients who can most benefit from an aberration‐specific targeted therapy across multiple cancer types is important. We propose an adaptive Bayesian clinical trial design for patient allocation and subpopulation identification. We start with a decision theoretic approach, including a utility function and a probability model across all possible subpopulation models. The main features of the proposed design and population finding methods are the use of a flexible nonparametric Bayesian survival regression based on a random covariate‐dependent partition of patients, and decisions based on a flexible utility function that reflects the requirement of the clinicians appropriately and realistically, and the adaptive allocation of patients to their superior treatments. Through extensive simulation studies, the new method is demonstrated to achieve desirable operating characteristics and compares favorably against the alternatives.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here